What is Langerhans cell histiocytosis?
Langerhans cell histiocytosis (LCH) is a rare disorder characterized by the abnormal accumulation and behavior of Langerhans cells, a type of immune cell normally found in the skin and other organs. This condition can affect multiple organ systems, causing a wide range of symptoms from isolated bone lesions to life-threatening multi-organ involvement. LCH primarily affects children, with approximately 1 in 200,000 children diagnosed worldwide, though it can also occur in adults. While historically considered an inflammatory condition, LCH is now recognized as a clonal disorder with characteristics of both cancer and immune dysfunction.
Key statistics
| Prevalence | 1 in 200,000 children |
| Annual incidence | 2-10 cases per million children |
| Peak age of onset | 1-3 years |
| 5-year survival rate | 95% (single-system) to 80% (multi-system with risk organs) |
Symptoms
Common symptoms: Bone pain and swelling, skin rash, enlarged liver or spleen, excessive thirst and urination, chronic ear drainage, breathing difficulties, fever, weight loss.
The symptoms of LCH vary dramatically depending on which organs are affected. Bone involvement is most common, presenting as painful swellings, particularly in the skull, ribs, spine, pelvis, or long bones. Children may develop limping or refuse to walk. Skin manifestations can include a persistent rash resembling eczema or seborrheic dermatitis, often appearing on the scalp, behind the ears, or in the diaper area in infants.
Endocrine symptoms may include diabetes insipidus, causing excessive thirst and urination due to pituitary gland involvement. Growth hormone deficiency can lead to delayed growth. Lung involvement may cause persistent cough, chest pain, or breathing difficulties. Liver and spleen enlargement (hepatosplenomegaly) can occur in more severe cases, sometimes accompanied by jaundice or abdominal swelling.
Serious complications include central nervous system involvement, which may cause seizures, behavioral changes, or coordination problems, and pulmonary involvement in adults, which can lead to progressive lung scarring and respiratory failure.
Causes and risk factors
LCH is caused by genetic mutations that occur during a person’s lifetime (somatic mutations) rather than inherited mutations. The most common mutation affects the BRAF gene, specifically the BRAF V600E mutation, found in approximately 50-60% of LCH cases. Other mutations may involve genes in the same cellular pathway, including MAP2K1 and other MAPK pathway genes.
These mutations cause Langerhans cells to multiply uncontrollably and accumulate in various organs, leading to inflammation and tissue damage. The condition is considered clonal, meaning it arises from a single abnormal cell that divides repeatedly.
Risk factors for LCH are largely unknown. Unlike many cancers, there are no clear environmental, infectious, or lifestyle factors that increase risk. The condition appears to occur randomly, and most cases are sporadic with no family history. Very rarely, familial cases have been reported, but these represent less than 1% of all LCH cases.
Prevention
Currently, there are no evidence-based methods to prevent LCH since it results from spontaneous genetic mutations that occur during cell division. The sporadic nature of the condition means that standard cancer prevention strategies do not apply.
Genetic testing and counseling are not routinely recommended for families, as the vast majority of cases are not inherited. However, genetic testing of tumor tissue is increasingly used to identify specific mutations that can guide treatment decisions. Families with extremely rare cases of familial LCH may benefit from genetic counseling to understand recurrence risks.
Regular health monitoring and prompt medical attention for persistent symptoms remain the most effective strategies for early detection and treatment.
Complications
Without appropriate treatment, LCH can lead to serious and potentially life-threatening complications. Bone involvement may result in fractures, spinal instability, or permanent deformities. Dental problems can occur when the jaw bones are affected.
Endocrine complications include permanent diabetes insipidus requiring lifelong hormone replacement, growth hormone deficiency leading to short stature, and other pituitary hormone deficiencies. Liver involvement can progress to cirrhosis and liver failure. Lung complications may include pneumothorax (collapsed lung) and progressive pulmonary fibrosis.
Central nervous system involvement, occurring in 10-25% of patients, can cause neurodegeneration leading to cognitive impairment, coordination problems, behavioral changes, and seizures. These neurological complications often progress despite treatment of systemic disease.
Secondary cancers may develop years after LCH treatment, particularly in patients who received intensive chemotherapy or radiation therapy.
Diagnosis
Diagnosing LCH requires a combination of clinical evaluation, imaging studies, and tissue biopsy with specialized testing. Initial assessment typically includes a complete medical history and physical examination, focusing on areas commonly affected by LCH.
Imaging studies include skeletal surveys or whole-body MRI to detect bone lesions, chest X-rays or CT scans for pulmonary involvement, and abdominal ultrasound or MRI to evaluate liver and spleen enlargement.
Laboratory tests may reveal elevated inflammatory markers, liver function abnormalities, or hormonal imbalances suggesting pituitary involvement.
Definitive diagnosis requires tissue biopsy showing characteristic Langerhans cell infiltration with positive immunostaining for CD1a and CD68, and electron microscopy demonstrating Birbeck granules or positive Langerin staining. Genetic testing of biopsy tissue to identify BRAF V600E or other mutations is increasingly performed to guide treatment selection.
Additional specialized tests may include bone marrow biopsy in multi-system disease and comprehensive endocrine evaluation if pituitary involvement is suspected.
Treatment
Treatment for LCH depends on the extent and location of disease involvement. For single-system bone disease, observation may be appropriate for asymptomatic lesions, while symptomatic lesions may require local treatment with corticosteroid injections or surgical curettage.
Multi-system disease typically requires systemic chemotherapy. First-line treatment often includes vinblastine combined with corticosteroids. For patients who do not respond adequately, second-line options include cytarabine (also known as cytosine arabinoside) or cladribine.
Targeted therapy with BRAF inhibitors or MEK inhibitors is emerging as a promising treatment option, particularly for patients with refractory disease or those harboring specific mutations. These treatments are currently being studied in clinical trials.
Radiation therapy may be considered for isolated bone lesions in adults or for CNS involvement, though it is generally avoided in young children due to long-term side effects.
Supportive care includes hormone replacement therapy for endocrine deficiencies, particularly desmopressin for diabetes insipidus, and growth hormone replacement when indicated.
Prognosis
The prognosis for LCH varies significantly based on age at diagnosis, extent of disease, and organs involved. Patients with single-system disease, particularly isolated bone involvement, have an excellent prognosis with 5-year survival rates exceeding 95%.
Multi-system disease without involvement of “risk organs” (liver, spleen, or bone marrow) also has a favorable outlook, with 5-year survival rates of 90-95%. However, when risk organs are involved, particularly in children under 2 years of age, the prognosis is more guarded, with 5-year survival rates of 70-80%.
Long-term complications can significantly impact quality of life, even in survivors. Endocrine dysfunction affects 10-50% of patients, with diabetes insipidus being most common. Growth hormone deficiency, occurring in 10-20% of patients, may require ongoing treatment through adolescence.
Neurodegeneration, a late complication affecting 10-25% of patients, can cause progressive cognitive and motor impairment that may not respond to treatment of active LCH.
Quality of life
Living with LCH requires ongoing medical management and attention to potential late effects. Many patients and families find that maintaining a structured routine helps manage the physical and emotional challenges of the condition.
Diet and nutrition support is important, especially during active treatment when appetite may be reduced. Adequate hydration is crucial for patients with diabetes insipidus. Physical activity should be maintained as tolerated, with modifications for bone involvement or respiratory symptoms.
School and work accommodations may be necessary during active treatment or for patients with cognitive effects from CNS involvement. Educational support and individualized learning plans can help children maintain academic progress.
Mental health support is essential, as both patients and families may experience anxiety, depression, or adjustment difficulties. Counseling services and support groups can provide valuable coping strategies.
Regular follow-up care is critical for monitoring disease status and managing late effects. Patients often benefit from care coordination through specialized centers familiar with LCH management.
Pregnancy and fertility
LCH can affect fertility through endocrine complications, particularly pituitary hormone deficiencies. Women with LCH may experience irregular menstruation or fertility issues requiring hormone replacement or fertility treatments.
Pregnancy outcomes are generally favorable for women with inactive LCH, though careful monitoring is recommended. Some medications used to treat LCH may not be safe during pregnancy, requiring treatment modifications for women of childbearing age.
Genetic counseling may be beneficial for patients considering pregnancy, though the risk of transmission to offspring is extremely low given the sporadic nature of most LCH cases.
Children
LCH predominantly affects children, with peak incidence in the first three years of life. Pediatric management requires specialized expertise in childhood cancer care and attention to developmental needs.
Treatment considerations in children include minimizing long-term side effects while maintaining treatment effectiveness. Growth and development monitoring is essential, with particular attention to endocrine function, bone development, and cognitive development.
Educational support and family counseling are important components of comprehensive care. Many children with LCH can attend school regularly with appropriate accommodations during treatment periods.
When to see a doctor
Urgent medical attention is needed for severe symptoms including difficulty breathing, severe abdominal pain, persistent high fever, signs of increased intracranial pressure (severe headache, vomiting, vision changes), or any neurological symptoms such as seizures or altered consciousness.
Routine medical evaluation should be sought for persistent bone pain or swelling, non-healing skin rashes, excessive thirst and urination lasting more than a few days, chronic ear drainage, or unexplained weight loss and fatigue.
Given the rarity of LCH, symptoms may initially be attributed to more common conditions. Persistence or progression of symptoms warrants thorough evaluation, particularly when multiple organ systems appear to be involved.
Regional context
Limited epidemiological data exists for LCH prevalence in the Caucasus region, including Georgia, Armenia, and Azerbaijan. The condition is likely to occur at similar rates to global estimates, though regional genetic variations and environmental factors may influence disease characteristics.
Healthcare infrastructure and access to specialized pediatric oncology services may vary across the region. International collaboration and telemedicine consultations can help ensure patients receive optimal care when local expertise is limited.
The Georgian Medical Journal welcomes contributions from regional healthcare providers regarding local experience with LCH diagnosis, treatment, and outcomes to better understand the disease burden and healthcare needs in this geographic area.
Research and clinical trials
Current research focuses on better understanding the genetic basis of LCH and developing targeted therapies. Clinical trials are investigating BRAF inhibitors, MEK inhibitors, and other targeted agents for both pediatric and adult patients with refractory or high-risk disease.
The international LCH-IV trial is evaluating treatment strategies for patients with multi-system disease, while studies of CNS-LCH are investigating approaches to prevent or treat neurodegeneration.
Biomarker research aims to identify patients at highest risk for complications and those most likely to benefit from specific treatments. Cell-free DNA testing may allow for non-invasive monitoring of treatment response.
Patients and families can find information about current clinical trials through ClinicalTrials.gov or by contacting specialized LCH treatment centers. Participation in research studies can provide access to novel treatments while contributing to improved understanding of this rare condition.
Frequently asked questions
Is LCH a type of cancer?
LCH has characteristics of both cancer and inflammatory conditions. While it involves clonal cell proliferation like cancer, it often responds to anti-inflammatory treatments and may spontaneously resolve. It is classified as a histiocytic disorder rather than a traditional cancer.
Can LCH be cured?
Many patients with LCH can be successfully treated and remain disease-free long-term. However, the condition may recur, and some patients develop chronic complications requiring ongoing management. Complete cure rates vary depending on disease extent and patient age.
Is LCH hereditary?
LCH is not typically inherited. Over 99% of cases are sporadic, occurring due to random genetic mutations during a person’s lifetime. Families with multiple affected members are extremely rare.
What is the difference between pediatric and adult LCH?
Pediatric LCH more commonly involves multiple organs and may have better treatment response. Adult LCH often presents with lung involvement and may have a more chronic course. Treatment approaches may differ based on age and disease characteristics.
How long does LCH treatment take?
Treatment duration varies widely depending on disease severity and response. Some patients with single-system disease may require only local treatment or observation, while multi-system disease typically requires 6-12 months of systemic therapy with ongoing monitoring for years.
Support and resources
Patient Organizations:
• Histiocytosis Association: https://histio.org
• Histiocytosis Research Trust (UK): https://www.histio.org.uk
International Resources:
• Orphanet: https://www.orpha.net
• National Organization for Rare Disorders (NORD): https://rarediseases.org
• EURORDIS: https://www.eurordis.org
• WHO International Classification of Diseases: https://icd.who.int
Clinical Trial Information:
• ClinicalTrials.gov: https://clinicaltrials.gov
Related conditions
Erdheim-Chester disease
Rosai-Dorfman disease
Juvenile xanthogranuloma
Hemophagocytic lymphohistiocytosis
Acute lymphoblastic leukemia
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Langerhans cell histiocytosis.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/langerhans-cell-histiocytosis/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?